T-DM1 after T-DXd for advanced HER2-positive breast cancer
Part of Cancer, Skin clinical trials.
This trial looks at whether a different targeted therapy, T-DM1, can work for women with advanced HER2-positive breast cancer after they have already tried another targeted therapy called T-DXd (Enhertu). If you have progressed while on T-DXd and have not had more than three previous treatments for advanced cancer, you may be able to join.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have HER2-positive breast cancer that has spread to other parts of the body or cannot be fully removed by surgery.
- You have already been treated with the targeted therapy T-DXd (Enhertu) for your advanced cancer.
- Your doctor plans to start T-DM1 (Kadcyla) as your very next treatment after T-DXd stops working.
- You have not had T-DM1 before for your advanced cancer.
- You have not had more than 3 other treatments for your advanced cancer before starting T-DXd.
- You have not received other chemotherapy or antibody-drug conjugates between T-DXd and T-DM1 (hormone therapy alone is okay).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new antibody-drug conjugate (DP303c) against an existing one, T-DM1, in people with HER2-positive advanced breast cancer who have already been treated with trastuzumab and a taxane. The goal is to see if the new drug works better or has fewer side effects.
This study looks at how well the drug T-DXd (Enhertu) works against breast cancer that has spread or can't be removed with surgery. It includes patients with any level of HER2 protein, so it might be an option even if your cancer has low HER2.
This trial is for people with advanced HER2-positive solid tumors (cancers that cannot be removed by surgery or have spread). It tests the drug T-DXd (also called Enhertu) when your doctor has already decided it's the right treatment for you and you have no other good options.
This study follows women with advanced breast cancer (metastatic) who have hormone-receptor positive tumors and low HER2 levels, to see how well a new drug called Trastuzumab Deruxtecan works when used in routine clinical care after prior hormone therapy.
This trial compares two treatments for advanced breast cancer that is HR-positive, HER2-low or ultralow, and a non-luminal subtype. It tests if a targeted antibody-drug conjugate (T-DXd) works better than the usual first-line therapy combining a CDK4/6 inhibitor with hormone therapy. This study is for people who have not had any treatment for advanced disease.
This trial tests a targeted therapy called Trastuzumab Deruxtecan (T-DXd) for people with HER2-positive breast cancer that has spread or cannot be removed. It is for those who have not yet received any chemotherapy or HER2-targeted treatment for metastatic disease. The study also focuses on managing side effects early, using digital tools to track symptoms.
Hear when a new Cancer of Breast trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.